|(Sempermed)_______|___________________|___________________|___________________| 
|Sales_____________|______________192.9|______________>100%|_______________77.5| 
|EBITDA____________|______________105.3|______________>100%|________________4.8| 
|EBIT______________|______________100.2|______________>100%|________________4.3| 
 
 
 
 
 
 
 
 
 
 
 
 
Further inquiry note: 
Monika Riedel 
Director Group Brand Management, Corporate Spokesperson 
+43 676 8715 8620 
monika.riedel@semperitgroup.com 
 
Judit Helenyi 
Director Investor Relations 
+43 676 8715 8310 
judit.helenyi@semperitgroup.com 
 
www.semperitgroup.com 
 
end of announcement                         euro adhoc 
=------------------------------------------------------------------------------- 
 
 
Attachments with Announcement: 
=--------------------------------------------- 
http://resources.euroadhoc.com/documents/15/5/10725755/1/2021-05-19_Semperit_Press_Release_Q1_2021.pdf

(END) Dow Jones Newswires

May 19, 2021 01:39 ET (05:39 GMT)